

**VIVIMED LABS LIMITED - CONSOLIDATED**  
**SEGMENT-WISE FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE**  
**LISTING AGREEMENT**

(INR in mn)

Particulars	3 Months ended		3 Months ended		12 Months
	Unaudited		Unaudited		Audited
	30.06.12	30.06.11	30.06.12	30.06.11	31.03.12
<b>1. Segment Revenue</b> (Net Sales/Income from each segment should be disclosed under this head)					
a. Speciality Chemicals Business	10,516.66	10,251.74	10,516.66	10,251.74	42,628.52
b. Pharma Business	19,084.10	3,778.53	19,084.10	3,778.53	34,544.88
<b>Total</b>	<b>29,600.76</b>	<b>14,030.27</b>	<b>29,600.76</b>	<b>14,030.27</b>	<b>77,173.41</b>
Less : Inter Segment Revenue	2,349.09	1,976.16	2,349.09	1,976.16	8,238.49
<b>Net sales / Income from Operations</b>	<b>27,251.66</b>	<b>12,054.11</b>	<b>27,251.66</b>	<b>12,054.11</b>	<b>68,934.92</b>
<b>2. Segment Results(Profit)(+)/Loss(-) before tax and interest from each segment</b>					
a. Speciality Chemicals Business	1,969.79	1,504.19	1,969.79	1,504.19	6,006.96
b. Pharma Business	2,811.19	702.14	2,811.19	702.14	4,612.10
<b>Total</b>	<b>4,780.98</b>	<b>2,206.33</b>	<b>4,780.98</b>	<b>2,206.33</b>	<b>10,619.06</b>
Less: 1. Interest	1,589.06	650.65	1,589.06	650.65	2,837.54
2. Other Un-allocable Expenditure net off	-	-	-	-	-
3. Un-allocable Income	-	-	-	-	-
<b>Total Profit Before Tax</b>	<b>3,191.92</b>	<b>1,555.68</b>	<b>3,191.92</b>	<b>1,555.68</b>	<b>7,781.52</b>
<b>3. Capital Employed</b> (Segment Assets - Segment Liabilities)					
a. Speciality Chemicals Business	73,722.17	49,530.42	73,722.17	49,530.42	68,234.97
b. Pharma Business	43,555.23	6,789.12	43,555.23	6,789.12	40,330.25
<b>Total</b>	<b>1,17,277.41</b>	<b>56,319.54</b>	<b>1,17,277.41</b>	<b>56,319.54</b>	<b>1,08,565.22</b>

For Vivimed Labs Limited

Place : Hyderabad  
Date : 13 / 08 / 2012

(SANTOSH VARALWAR)  
MANAGING DIRECTOR & CEO